KRAS and cancer: In PDA and CRC, activating mutations of the MAPK pathway (e.g., in KRAS and BRAF) and loss of tumor suppressor TP53 are common [41, 42], and these mutations play important roles in the reprogramming of cancer metabolism [11, 18, 43].